Ryan Elliott
@ryanelliott.bsky.social
Hematology Resident Physician | Former High School Teacher | Piano Enthusiast | Proud Newfoundlander | Just a general guy born in the 90s
https://buymeacoffee.com/ryanelliott
https://buymeacoffee.com/ryanelliott
📚 This T-cell NHL diagnostic slide has been circulating and provides a nice framework
#medsky #hemesky #hemeonc #lymphoma #pathsky #hemepath #Tcells #cellmarkers #biology #hematology #medicine #pathology #oncology #oncsky #diagnostics #meded
#medsky #hemesky #hemeonc #lymphoma #pathsky #hemepath #Tcells #cellmarkers #biology #hematology #medicine #pathology #oncology #oncsky #diagnostics #meded
September 17, 2025 at 9:20 AM
📚 This T-cell NHL diagnostic slide has been circulating and provides a nice framework
#medsky #hemesky #hemeonc #lymphoma #pathsky #hemepath #Tcells #cellmarkers #biology #hematology #medicine #pathology #oncology #oncsky #diagnostics #meded
#medsky #hemesky #hemeonc #lymphoma #pathsky #hemepath #Tcells #cellmarkers #biology #hematology #medicine #pathology #oncology #oncsky #diagnostics #meded
Reposted by Ryan Elliott
Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL
#CLL #Hematology
www.onclive.com/view/final-c...
#CLL #Hematology
www.onclive.com/view/final-c...
Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL | OncLive
Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.
www.onclive.com
September 16, 2025 at 12:43 PM
Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL
#CLL #Hematology
www.onclive.com/view/final-c...
#CLL #Hematology
www.onclive.com/view/final-c...
Open for members
Secure your top hotel pick
Don’t wait! Register 👇
Claim your spot now: https://bit.ly/46VqNXj #ASH25 #ASHaiku
Secure your top hotel pick
Don’t wait! Register 👇
Claim your spot now: https://bit.ly/46VqNXj #ASH25 #ASHaiku
September 8, 2025 at 5:08 PM
🩸 ISTH DIC score (overt ≥ 5)
Plt <50=2; 50–100=1
PT >6s=2; 3–6s=1
Fibrinogen <1.0g/L=1
D-dimer: >3× ULN=3; 1–3× ULN=2; none=0
#hemesky #medsky #coag #benignheme
Plt <50=2; 50–100=1
PT >6s=2; 3–6s=1
Fibrinogen <1.0g/L=1
D-dimer: >3× ULN=3; 1–3× ULN=2; none=0
#hemesky #medsky #coag #benignheme
September 8, 2025 at 3:24 AM
🩸 ISTH DIC score (overt ≥ 5)
Plt <50=2; 50–100=1
PT >6s=2; 3–6s=1
Fibrinogen <1.0g/L=1
D-dimer: >3× ULN=3; 1–3× ULN=2; none=0
#hemesky #medsky #coag #benignheme
Plt <50=2; 50–100=1
PT >6s=2; 3–6s=1
Fibrinogen <1.0g/L=1
D-dimer: >3× ULN=3; 1–3× ULN=2; none=0
#hemesky #medsky #coag #benignheme
Reposted by Ryan Elliott
Join us on October 25 for a packed day of thrombosis education for healthcare professionals. Register today at thrombosiscanada.ca/2025Conference
July 4, 2025 at 7:19 PM
Join us on October 25 for a packed day of thrombosis education for healthcare professionals. Register today at thrombosiscanada.ca/2025Conference
Reposted by Ryan Elliott
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL @mdanderson.bsky.social @societyofhemonc.bsky.social #SOHO2025 #lymsm #hematology
www.onclive.com/view/mosunet...
www.onclive.com/view/mosunet...
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL
Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.
www.onclive.com
September 6, 2025 at 5:11 PM
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL @mdanderson.bsky.social @societyofhemonc.bsky.social #SOHO2025 #lymsm #hematology
www.onclive.com/view/mosunet...
www.onclive.com/view/mosunet...
🩺 Differentiation Syndrome
- complication that can occur during treatment of APL w/ ATRA+ATO
Clinical:
⬆️ WBCs
⬆️ Fever
⬆️ edema/body weight/pulmonary infiltrates
Mgmt:
- high-dose steroids
- cytoreduction
- antipyretics / cxs / abx for FN
- diuresis
#hemesky #hemeonc #medsky #APL #APML #leukemia
- complication that can occur during treatment of APL w/ ATRA+ATO
Clinical:
⬆️ WBCs
⬆️ Fever
⬆️ edema/body weight/pulmonary infiltrates
Mgmt:
- high-dose steroids
- cytoreduction
- antipyretics / cxs / abx for FN
- diuresis
#hemesky #hemeonc #medsky #APL #APML #leukemia
September 6, 2025 at 4:54 AM
Not hard to tell that I’m currently on thrombosis! Having a good experience with the team here at McMaster. #thrombosis #hemesky #hematology
August 17, 2025 at 3:30 PM
Not hard to tell that I’m currently on thrombosis! Having a good experience with the team here at McMaster. #thrombosis #hemesky #hematology
Reposted by Ryan Elliott
"Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation."
Publié en juillet dans J Thromb Haemost.
#MedSky #DIC
www.sciencedirect.com/science/arti...
Publié en juillet dans J Thromb Haemost.
#MedSky #DIC
www.sciencedirect.com/science/arti...
Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation
Compelling evidence supports the need to update the 2001 definition and diagnosis of disseminated intravascular coagulation (DIC) to reflect our curre…
www.sciencedirect.com
July 18, 2025 at 1:32 PM
"Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation."
Publié en juillet dans J Thromb Haemost.
#MedSky #DIC
www.sciencedirect.com/science/arti...
Publié en juillet dans J Thromb Haemost.
#MedSky #DIC
www.sciencedirect.com/science/arti...
🩸📖 NEJM 2003: CLOT trial - 676 patients w/ cancer-associated thrombosis (CAT) - Dalteparin vs warfarin.
Dalteparin dose: 200 IU/kg sc daily ×1/12 → 150 IU/kg daily ×5/12 (total 6 months).
Outcome: ↓ recurrent VTE; no ↑ major bleed in the group who received dalteparin.
#hemesky #thrombosis #medsky
Dalteparin dose: 200 IU/kg sc daily ×1/12 → 150 IU/kg daily ×5/12 (total 6 months).
Outcome: ↓ recurrent VTE; no ↑ major bleed in the group who received dalteparin.
#hemesky #thrombosis #medsky
August 17, 2025 at 3:06 PM
🩸📖 NEJM 2003: CLOT trial - 676 patients w/ cancer-associated thrombosis (CAT) - Dalteparin vs warfarin.
Dalteparin dose: 200 IU/kg sc daily ×1/12 → 150 IU/kg daily ×5/12 (total 6 months).
Outcome: ↓ recurrent VTE; no ↑ major bleed in the group who received dalteparin.
#hemesky #thrombosis #medsky
Dalteparin dose: 200 IU/kg sc daily ×1/12 → 150 IU/kg daily ×5/12 (total 6 months).
Outcome: ↓ recurrent VTE; no ↑ major bleed in the group who received dalteparin.
#hemesky #thrombosis #medsky
🩸Cancer-associated Thrombosis Trials: LMWH more effective than VKAs
CANTHANOX 2002:
Enoxaparin vs VKA
CLOT 2003:
Dalteparin vs VKA
ONCENOX 2006:
Enoxaparin vs VKA
LITE 2006:
Tinzaparin vs VKA
CATCH 2015:
Tinzaparin vs VKA
#thrombosis #clinicalTrials #hemesky #medsky #IMsky #oncology #hemeonc
CANTHANOX 2002:
Enoxaparin vs VKA
CLOT 2003:
Dalteparin vs VKA
ONCENOX 2006:
Enoxaparin vs VKA
LITE 2006:
Tinzaparin vs VKA
CATCH 2015:
Tinzaparin vs VKA
#thrombosis #clinicalTrials #hemesky #medsky #IMsky #oncology #hemeonc
August 15, 2025 at 3:40 AM
🩸Cancer-associated Thrombosis Trials: LMWH more effective than VKAs
CANTHANOX 2002:
Enoxaparin vs VKA
CLOT 2003:
Dalteparin vs VKA
ONCENOX 2006:
Enoxaparin vs VKA
LITE 2006:
Tinzaparin vs VKA
CATCH 2015:
Tinzaparin vs VKA
#thrombosis #clinicalTrials #hemesky #medsky #IMsky #oncology #hemeonc
CANTHANOX 2002:
Enoxaparin vs VKA
CLOT 2003:
Dalteparin vs VKA
ONCENOX 2006:
Enoxaparin vs VKA
LITE 2006:
Tinzaparin vs VKA
CATCH 2015:
Tinzaparin vs VKA
#thrombosis #clinicalTrials #hemesky #medsky #IMsky #oncology #hemeonc
CARAVAGGIO 2020 (1,170 pts):
Apixaban vs dalteparin for cancer VTE. Recurrent VTE 5.6 % vs 7.9 % (non-inf). Major bleed 3.8 % vs 4.0 %; no extra GI bleed. Bottom line: apixaban noninferior to dalteparin without increase in major bleeding in cancer-associated VTE. #medsky #hemesky #thrombosis
Apixaban vs dalteparin for cancer VTE. Recurrent VTE 5.6 % vs 7.9 % (non-inf). Major bleed 3.8 % vs 4.0 %; no extra GI bleed. Bottom line: apixaban noninferior to dalteparin without increase in major bleeding in cancer-associated VTE. #medsky #hemesky #thrombosis
August 6, 2025 at 4:03 AM
CARAVAGGIO 2020 (1,170 pts):
Apixaban vs dalteparin for cancer VTE. Recurrent VTE 5.6 % vs 7.9 % (non-inf). Major bleed 3.8 % vs 4.0 %; no extra GI bleed. Bottom line: apixaban noninferior to dalteparin without increase in major bleeding in cancer-associated VTE. #medsky #hemesky #thrombosis
Apixaban vs dalteparin for cancer VTE. Recurrent VTE 5.6 % vs 7.9 % (non-inf). Major bleed 3.8 % vs 4.0 %; no extra GI bleed. Bottom line: apixaban noninferior to dalteparin without increase in major bleeding in cancer-associated VTE. #medsky #hemesky #thrombosis
Lesson from this past week:
Isolated elevation of anticardiolipin IgM does not meet laboratory criteria for antiphospholipid syndrome! According to EULAR 2023 guidelines below. #medsky #IMsky #rheumsky #hemesky #antiphospholipid #thrombosis
Isolated elevation of anticardiolipin IgM does not meet laboratory criteria for antiphospholipid syndrome! According to EULAR 2023 guidelines below. #medsky #IMsky #rheumsky #hemesky #antiphospholipid #thrombosis
August 6, 2025 at 3:34 AM
Lesson from this past week:
Isolated elevation of anticardiolipin IgM does not meet laboratory criteria for antiphospholipid syndrome! According to EULAR 2023 guidelines below. #medsky #IMsky #rheumsky #hemesky #antiphospholipid #thrombosis
Isolated elevation of anticardiolipin IgM does not meet laboratory criteria for antiphospholipid syndrome! According to EULAR 2023 guidelines below. #medsky #IMsky #rheumsky #hemesky #antiphospholipid #thrombosis
Reposted by Ryan Elliott
Ven is effective (91% ORR) and well tolerated in octogenarians, but 43% hd treatment holds and 32% prolonged ramp-up. buff.ly/lNgBN1r #hemesky
August 4, 2025 at 12:02 PM
Ven is effective (91% ORR) and well tolerated in octogenarians, but 43% hd treatment holds and 32% prolonged ramp-up. buff.ly/lNgBN1r #hemesky
Monoclonal Gammopathy: Paraneoplastic Neuropathy 🧠🩸
AL Amyloidosis: painful + length-dependent + sensory > motor
POEMS: symmetric disabling demyelinating polyneuropathy
DADS-M: distal loss of proprioception + demyelinating + coarse tremor + mild motor weakness
#hemesky #myeloma #medsky #neurosky
AL Amyloidosis: painful + length-dependent + sensory > motor
POEMS: symmetric disabling demyelinating polyneuropathy
DADS-M: distal loss of proprioception + demyelinating + coarse tremor + mild motor weakness
#hemesky #myeloma #medsky #neurosky
August 4, 2025 at 2:26 PM
Reposted by Ryan Elliott
Chronic myeloid leukemia is a myeloproliferative neoplasm.
This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia.
https://ja.ma/4mlR6ez
This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia.
https://ja.ma/4mlR6ez
May 19, 2025 at 10:30 AM
Chronic myeloid leukemia is a myeloproliferative neoplasm.
This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia.
https://ja.ma/4mlR6ez
This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia.
https://ja.ma/4mlR6ez
Reposted by Ryan Elliott
Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma
buff.ly/bbBzTQG #hemesky #lymphoidneoplasia
buff.ly/bbBzTQG #hemesky #lymphoidneoplasia
June 2, 2025 at 3:04 PM
Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma
buff.ly/bbBzTQG #hemesky #lymphoidneoplasia
buff.ly/bbBzTQG #hemesky #lymphoidneoplasia
🔬🩸Hemoglobin development (some fundamentals!)
Embryo
Hb Gower I = ζ2ε2
Hb Gower II = α2ε2
Hb Portland = ζ2γ2
Fetus
HbF = α2γ2
Adult
HbA = α2β2 ~97%
HbA2 = α2δ2 ~2–3%
HbF <1%
#hemesky #medsky #IMsky #benignheme #hemoglobin #pediatrics
Embryo
Hb Gower I = ζ2ε2
Hb Gower II = α2ε2
Hb Portland = ζ2γ2
Fetus
HbF = α2γ2
Adult
HbA = α2β2 ~97%
HbA2 = α2δ2 ~2–3%
HbF <1%
#hemesky #medsky #IMsky #benignheme #hemoglobin #pediatrics
May 5, 2025 at 2:08 PM
🔬🩸Hemoglobin development (some fundamentals!)
Embryo
Hb Gower I = ζ2ε2
Hb Gower II = α2ε2
Hb Portland = ζ2γ2
Fetus
HbF = α2γ2
Adult
HbA = α2β2 ~97%
HbA2 = α2δ2 ~2–3%
HbF <1%
#hemesky #medsky #IMsky #benignheme #hemoglobin #pediatrics
Embryo
Hb Gower I = ζ2ε2
Hb Gower II = α2ε2
Hb Portland = ζ2γ2
Fetus
HbF = α2γ2
Adult
HbA = α2β2 ~97%
HbA2 = α2δ2 ~2–3%
HbF <1%
#hemesky #medsky #IMsky #benignheme #hemoglobin #pediatrics
Reposted by Ryan Elliott
JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management
#MPNsm #hematology #oncology
www.onclive.com/view/jak-inh...
#MPNsm #hematology #oncology
www.onclive.com/view/jak-inh...
JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management
Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.
www.onclive.com
February 19, 2025 at 8:46 PM
JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management
#MPNsm #hematology #oncology
www.onclive.com/view/jak-inh...
#MPNsm #hematology #oncology
www.onclive.com/view/jak-inh...
Reposted by Ryan Elliott
Workin. CML in a 27 Year old. #haematology #hematology
February 20, 2025 at 11:40 AM
Workin. CML in a 27 Year old. #haematology #hematology
💊 Abatacept
Humanized protein construct from recombinant DNA (CTLA4 + IgG1 Fc) grown in hamster ovary cells.
Selectively binds to CD80/86 on APCs, inhibiting CD80/86-CD28 costimulatory signal essential for full T-cell activation.
#medsky #IMsky #rheumsky #biologics
(Herrero-Beaumont et al., 2012)
Humanized protein construct from recombinant DNA (CTLA4 + IgG1 Fc) grown in hamster ovary cells.
Selectively binds to CD80/86 on APCs, inhibiting CD80/86-CD28 costimulatory signal essential for full T-cell activation.
#medsky #IMsky #rheumsky #biologics
(Herrero-Beaumont et al., 2012)
February 6, 2025 at 12:21 PM
💊 Abatacept
Humanized protein construct from recombinant DNA (CTLA4 + IgG1 Fc) grown in hamster ovary cells.
Selectively binds to CD80/86 on APCs, inhibiting CD80/86-CD28 costimulatory signal essential for full T-cell activation.
#medsky #IMsky #rheumsky #biologics
(Herrero-Beaumont et al., 2012)
Humanized protein construct from recombinant DNA (CTLA4 + IgG1 Fc) grown in hamster ovary cells.
Selectively binds to CD80/86 on APCs, inhibiting CD80/86-CD28 costimulatory signal essential for full T-cell activation.
#medsky #IMsky #rheumsky #biologics
(Herrero-Beaumont et al., 2012)
Reposted by Ryan Elliott
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
#mmsm #Hematology
www.onclive.com/view/isatuxi...
#mmsm #Hematology
www.onclive.com/view/isatuxi...
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
www.onclive.com
January 22, 2025 at 4:39 PM
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
#mmsm #Hematology
www.onclive.com/view/isatuxi...
#mmsm #Hematology
www.onclive.com/view/isatuxi...
Reposted by Ryan Elliott
This recently published study highlights the prognostic significance of high-risk cytogenetic abnormalities in multiple myeloma. Genetic alterations like t(4;14), del(17p), and +1q are linked to poorer prognosis and shorter survival #MM #hematology 👉https://bit.ly/3PzY1BT
January 23, 2025 at 9:30 AM
This recently published study highlights the prognostic significance of high-risk cytogenetic abnormalities in multiple myeloma. Genetic alterations like t(4;14), del(17p), and +1q are linked to poorer prognosis and shorter survival #MM #hematology 👉https://bit.ly/3PzY1BT
🩸Large Granular Lymphocytic Leukemia
Indolent clonal proliferation of mature cytotoxic T cells
- Neutropenia/anemia
- a/w autoimmunity
- CD8+ T cells w/ NK cell markers
- intrasinusoidal bone marrow/spleen/liver path
~50% STAT3 / STAT5b mutation
#hemesky #pathsly #hemepath #IMsky #medsky #leukemia
Indolent clonal proliferation of mature cytotoxic T cells
- Neutropenia/anemia
- a/w autoimmunity
- CD8+ T cells w/ NK cell markers
- intrasinusoidal bone marrow/spleen/liver path
~50% STAT3 / STAT5b mutation
#hemesky #pathsly #hemepath #IMsky #medsky #leukemia
January 3, 2025 at 6:05 AM
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
December 29, 2024 at 3:11 AM